This paper reviews the existing evidence supporting the efficacy and safety of rFVIIa in treating bleeding manifestations in patients with thrombocytopenia or those with excessive anticoagulation with warfarin. Currently this is in the form of case report or small series which showed efficacy of rFVIIa in reducing bleeding, shortening of bleeding time or reduction of INR. Large randomized studies are required to prove these points.

– M. Aldouri